Alnylam and Genzyme Form Alliance to Develop and Commercialize RNAi Therapeutics in Asia
[at noodls] – – Genzyme to Advance ALN-TTR02 and ALN-TTRsc Programs as Breakthrough Therapies for Patients with ATTR in Japan and in the Broader Asian Market – – Alnylam to Receive $22.5 Million in Upfront Payment in … moreView todays social media effects on ALNYView the latest stocks trending across Twitter. Click to view dashboard […]